<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03574805</url>
  </required_header>
  <id_info>
    <org_study_id>PRS-060-PCS_07_18</org_study_id>
    <nct_id>NCT03574805</nct_id>
  </id_info>
  <brief_title>Study of Multiple Doses of PRS-060 Administered by Oral Inhalation in Subjects With Mild Asthma</brief_title>
  <official_title>A Dose-Escalating, Single-Blind Study to Assess the Safety, Tolerability, and Pharmacokinetics of Multiple Doses of PRS-060 Administered by Oral Inhalation in Subjects With Mild Asthma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pieris Australia Pty Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pieris Australia Pty Ltd</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study of Multiple Doses of PRS-060 Administered by Oral Inhalation in Subjects with Mild&#xD;
      Asthma&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRS-060 is a drug candidate being developed for the treatment of asthma. The main purpose of&#xD;
      this study is to investigate the safety, tolerability, and pharmacokinetics of multiple doses&#xD;
      of PRS-060 administered by inhalation in subjects with mild asthma.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 26, 2018</start_date>
  <completion_date type="Actual">September 15, 2020</completion_date>
  <primary_completion_date type="Actual">September 15, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with adverse events (AEs) after an inhaled dose of PRS-060</measure>
    <time_frame>From time of dose until 30 days after dosing</time_frame>
    <description>The number of participants with treatment related AEs as assessed by current approved CTCAE version</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in blood pressure</measure>
    <time_frame>Screening, during treatment, 7 days after dosing (±1 day), and 30 days after dosing (±3 days).</time_frame>
    <description>To assess blood pressure (systolic and diastolic) as a criterion of safety and tolerability variables as measured in mm Hg)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in heart rate</measure>
    <time_frame>Screening, during treatment, 7 days after dosing (±1 day), and 30 days after dosing (±3 days).</time_frame>
    <description>To assess changes in beats per minute (BPM) as a criterion of safety and tolerability variables</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in body temperature</measure>
    <time_frame>Screening, during treatment, 7 days after dosing (±1 day), and 30 days after dosing (±3 days).</time_frame>
    <description>To assess changes in body temperature in degrees Celsius as a criterion of safety and tolerability variables</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in electrocardiograms (ECGs)</measure>
    <time_frame>Screening, during treatment, 7 days after dosing (±1 day), and 30 days after dosing (±3 days).</time_frame>
    <description>To assess changes in cardiovascular system function (change in QTC parameters) as a criterion of safety and tolerability variables</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in forced expiratory volume 1-second (FEV1) as part of spirometry</measure>
    <time_frame>Screening, during treatment and confinement, 7 days after dosing (±1 day), and 30 days after dosing (±3 days).</time_frame>
    <description>To assess changes in FEV1 as measured in mL as part of spirometry</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in forced vital capacity (FVC) as part of spirometry</measure>
    <time_frame>Screening, during treatment and confinement, 7 days after dosing (±1 day), and 30 days after dosing (±3 days).</time_frame>
    <description>To assess changes in FVC as measured by mL</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in peak expiratory flow rate (PEFR) as part of spirometry</measure>
    <time_frame>Screening, during treatment and confinement, 7 days after dosing (±1 day), and 30 days after dosing (±3 days).</time_frame>
    <description>To assess changes in PEFR as measured in L/min</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in sodium levels as part of standard serum chemistry panel</measure>
    <time_frame>Screening, during treatment, 7 days after dosing (±1 day), and 30 days after dosing (±3 days).</time_frame>
    <description>To asses changes in sodium levels as measured in mmol/L</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in potassium levels as part of standard serum chemistry panel</measure>
    <time_frame>Screening, during treatment, 7 days after dosing (±1 day), and 30 days after dosing (±3 days).</time_frame>
    <description>To assess changes in potassium levels as measured in mmol/L</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in chloride levels as part of standard serum chemistry panel</measure>
    <time_frame>Screening, during treatment, 7 days after dosing (±1 day), and 30 days after dosing (±3 days)</time_frame>
    <description>To assess changes in chloride levels as measured in mmol/L</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in bicarbonate levels as part of standard serum chemistry panel</measure>
    <time_frame>Screening, during treatment, 7 days after dosing (±1 day), and 30 days after dosing (±3 days).</time_frame>
    <description>To assess changes in bicarbonate levels as measured in mmol/L</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in blood urea nitrogen (BUN)/Urea levels as part of standard serum chemistry panel</measure>
    <time_frame>Screening, during treatment, 7 days after dosing (±1 day), and 30 days after dosing (±3 days).</time_frame>
    <description>To assess changes BUN/Urea levels as measured in mmol/L</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in creatinine levels as part of standard serum chemistry panel</measure>
    <time_frame>Screening, during treatment, 7 days after dosing (±1 day), and 30 days after dosing (±3 days).</time_frame>
    <description>To assess changes in creatinine levels as measured in umol/L</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in total protein levels as part of standard serum chemistry panel</measure>
    <time_frame>Screening, during treatment, 7 days after dosing (±1 day), and 30 days after dosing (±3 days).</time_frame>
    <description>To assess changes in total protein levels as measured in g/L</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in albumin levels as part of standard serum chemistry panel</measure>
    <time_frame>Screening, during treatment, 7 days after dosing (±1 day), and 30 days after dosing (±3 days).</time_frame>
    <description>To assess changes in albumin levels as measure in g/L</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in alkaline phosphate (ALP) levels as part of standard serum chemistry panel</measure>
    <time_frame>Screening, during treatment, 7 days after dosing (±1 day), and 30 days after dosing (±3 days).</time_frame>
    <description>To assess changes in ALP levels as measured in U/L</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in ALT levels as part of standard serum chemistry panel</measure>
    <time_frame>Screening, during treatment, 7 days after dosing (±1 day), and 30 days after dosing (±3 days).</time_frame>
    <description>To assess changes in ALT levels as measured in U/L</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in AST levels as part of standard serum chemistry panel</measure>
    <time_frame>Screening, during treatment, 7 days after dosing (±1 day), and 30 days after dosing (±3 days).</time_frame>
    <description>To assess changes in AST levels as measured in U/L</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in total bilirubin levels as part of standard serum chemistry panel</measure>
    <time_frame>Screening, during treatment, 7 days after dosing (±1 day), and 30 days after dosing (±3 days).</time_frame>
    <description>To assess changes in total bilirubin levels as measured in umol/L</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in direct bilirubin levels as part of standard serum chemistry panel</measure>
    <time_frame>Screening, during treatment, 7 days after dosing (±1 day), and 30 days after dosing (±3 days).</time_frame>
    <description>To assess changes in direct bilirubin levels as measured in umol/L</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in indirect bilirubin levels as part of standard serum chemistry panel</measure>
    <time_frame>Screening, during treatment, 7 days after dosing (±1 day), and 30 days after dosing (±3 days).</time_frame>
    <description>To assess changes in indirect bilirubin levels as measured in umol/L</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in amylase levels as part of standard serum chemistry panel</measure>
    <time_frame>Screening, during treatment, 7 days after dosing (±1 day), and 30 days after dosing (±3 days).</time_frame>
    <description>To assess changes in amylase levels as measured in U/L</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in lipase levels as part of standard serum chemistry panel</measure>
    <time_frame>Screening, during treatment, 7 days after dosing (±1 day), and 30 days after dosing (±3 days).</time_frame>
    <description>To assess changes in lipase levels as measured in U/L</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in uric acid levels as part of standard serum chemistry panel</measure>
    <time_frame>Screening, during treatment, 7 days after dosing (±1 day), and 30 days after dosing (±3 days).</time_frame>
    <description>To assess changes in uric acid levels as measured in mmol/L</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in creatine kinase (CK) levels as part of standard serum chemistry panel</measure>
    <time_frame>Screening, during treatment, 7 days after dosing (±1 day), and 30 days after dosing (±3 days).</time_frame>
    <description>To assess changes in CK levels as measured in U/L</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in calcium levels as part of standard serum chemistry panel</measure>
    <time_frame>Screening, during treatment, 7 days after dosing (±1 day), and 30 days after dosing (±3 days).</time_frame>
    <description>To assess changes in calcium levels as measured in mmol/L</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in magnesium levels as part of standard serum chemistry panel</measure>
    <time_frame>Screening, during treatment, 7 days after dosing (±1 day), and 30 days after dosing (±3 days).</time_frame>
    <description>To assess changes in magnesium levels as measured in mmol/L</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in lactate dehydrogenase (LDH) levels as part of standard serum chemistry panel.</measure>
    <time_frame>Screening, during treatment, 7 days after dosing (±1 day), and 30 days after dosing (±3 days).</time_frame>
    <description>To assess changes in LDH levels as measure in U/L</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in total immunoglobulin (IgG) levels as part of standard serum chemistry panel</measure>
    <time_frame>Screening, during treatment, 7 days after dosing (±1 day), and 30 days after dosing (±3 days).</time_frame>
    <description>To assess changes in total IgG levels as measured in g/L</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in total immunoglobulin (IgA) levels as part of standard serum chemistry panel</measure>
    <time_frame>Screening, during treatment, 7 days after dosing (±1 day), and 30 days after dosing (±3 days).</time_frame>
    <description>To assess changes in total IgA levels as measured in g/L</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in total immunoglobulin (IgE) levels as part of standard serum chemistry panel</measure>
    <time_frame>Screening, during treatment, 7 days after dosing (±1 day), and 30 days after dosing (±3 days).</time_frame>
    <description>To assess changes in total IgE levels as measured in lU/mL</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in total immunoglobulin (IgM) levels as part of standard serum chemistry panel</measure>
    <time_frame>Screening, during treatment, 7 days after dosing (±1 day), and 30 days after dosing (±3 days).</time_frame>
    <description>To assess changes in total IgM levels as measured in g/L</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in hematocrit as part of standard hematology panel</measure>
    <time_frame>Screening, during treatment, 7 days after dosing (±1 day), and 30 days after dosing (±3 days).</time_frame>
    <description>To assess changes in total hamatocrit levels as measured by %</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in hemoglobin levels as part of standard hematology panel</measure>
    <time_frame>Screening, during treatment, 7 days after dosing (±1 day), and 30 days after dosing (±3 days).</time_frame>
    <description>To assess changes in hemoglobin levels as measured by g/L</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in red blood cells (RBC) counts as part of standard hematology panel</measure>
    <time_frame>Screening, during treatment, 7 days after dosing (±1 day), and 30 days after dosing (±3 days).</time_frame>
    <description>To assess changes in red blood cells (RBC) counts as measured by 10^12/uL</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in platelet (PLT) counts as part of standard hematology panel</measure>
    <time_frame>Screening, during treatment, 7 days after dosing (±1 day), and 30 days after dosing (±3 days).</time_frame>
    <description>To assess changes in PLT counts as measured by 10^9/uL</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in white blood cells (WBC) counts as part of standard hematology panel</measure>
    <time_frame>Screening, during treatment, 7 days after dosing (±1 day), and 30 days after dosing (±3 days).</time_frame>
    <description>To assess changes in white blood cell (WBC) counts as measured by 10^9/uL</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in neutrophil percentage as part of standard hematology panel</measure>
    <time_frame>Screening, during treatment, 7 days after dosing (±1 day), and 30 days after dosing (±3 days).</time_frame>
    <description>To assess changes in neutrophil percentages as measured by %</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in lymphocyte percentage as part of standard hematology panel</measure>
    <time_frame>Screening, during treatment, 7 days after dosing (±1 day), and 30 days after dosing (±3 days).</time_frame>
    <description>To assess changes in lymphocyte percentage as measured by %</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in eosinophil percentage a part of standard hematology panel</measure>
    <time_frame>Screening, during treatment, 7 days after dosing (±1 day), and 30 days after dosing (±3 days).</time_frame>
    <description>To assess changes in eosinophil percentage as measured by %</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in basophil percentage as part of standard hematology panel</measure>
    <time_frame>Screening, during treatment, 7 days after dosing (±1 day), and 30 days after dosing (±3 days).</time_frame>
    <description>To assess changes basophil percentages as measured by %</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in monocyte percentage as part of standard hematology panel</measure>
    <time_frame>Screening, during treatment, 7 days after dosing (±1 day), and 30 days after dosing (±3 days).</time_frame>
    <description>To assess changes in monocyte percentage as measured by %</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in clarity as part of a standard urinalysis panel</measure>
    <time_frame>Screening, during treatment, 7 days after dosing (±1 day), and 30 days after dosing (±3 days).</time_frame>
    <description>To assess changes in clarity of the urine sample</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in specific gravity as part of a standard urinalysis panel</measure>
    <time_frame>Screening, during treatment, 7 days after dosing (±1 day), and 30 days after dosing (±3 days).</time_frame>
    <description>To assess changes in specific gravity of the urine sample</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in pH as part of a standard urinalysis panel</measure>
    <time_frame>Screening, during treatment, 7 days after dosing (±1 day), and 30 days after dosing (±3 days).</time_frame>
    <description>To assess changes in pH of the urine sample</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in protein levels as part of a standard urinalysis panel</measure>
    <time_frame>Screening, during treatment, 7 days after dosing (±1 day), and 30 days after dosing (±3 days).</time_frame>
    <description>To assess changes in protein levels of the urine sample</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in glucose levels as part of a standard urinalysis panel</measure>
    <time_frame>Screening, during treatment, 7 days after dosing (±1 day), and 30 days after dosing (±3 days).</time_frame>
    <description>To assess changes in glucose levels of the urine sample as measured by a positive or negative result.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in ketone levels as part of a standard urinalysis panel</measure>
    <time_frame>Screening, during treatment, 7 days after dosing (±1 day), and 30 days after dosing (±3 days).</time_frame>
    <description>To assess changes in ketone levels of the urine sample as measured by a positive or negative result</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in blood levels as part of a standard urinalysis panel</measure>
    <time_frame>Screening, during treatment, 7 days after dosing (±1 day), and 30 days after dosing (±3 days).</time_frame>
    <description>To assess changes in blood levels of the urine sample as measured by a positive or negative result.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in nitrite levels as part of a standard urinalysis panel</measure>
    <time_frame>Screening, during treatment, 7 days after dosing (±1 day), and 30 days after dosing (±3 days).</time_frame>
    <description>To assess changes in nitrite levels of the urine sample</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in leukocyte esterase levels as part of a standard urinalysis panel</measure>
    <time_frame>Screening, during treatment, 7 days after dosing (±1 day), and 30 days after dosing (±3 days).</time_frame>
    <description>To assess changes in leukocyte esterase levels of the urine sample</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PK assessment: Cmax (observed maximum serum concentration taken directly from the individual concentration-time curve)</measure>
    <time_frame>During treatment and confinement, 7 days after dosing (±1 day), and 30 days after dosing (±3 days).</time_frame>
    <description>Evaluation of the PK after receiving PRS-060</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK assessment: Tmax (time to reach maximum serum concentration, taken directly from the individual concentration-time curve)</measure>
    <time_frame>During treatment and confinement, 7 days after dosing (±1 day), and 30 days after dosing (±3 days).</time_frame>
    <description>Evaluation of the PK after receiving PRS-060</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK assessment: t1/2(terminal half-life)</measure>
    <time_frame>During treatment and confinement, 7 days after dosing (±1 day), and 30 days after dosing (±3 days).</time_frame>
    <description>Evaluation of the PK after receiving PRS-060</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK assessment: AUC (0-last) (area under the serum concentration-curve from time zero to the time of last quantifiable analyte concentration)</measure>
    <time_frame>During treatment and confinement, 7 days after dosing (±1 day), and 30 days after dosing (±3 days).</time_frame>
    <description>Evaluation of the PK after receiving PRS-060</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK assessment: AUC (area under the concentration-time curve in the serum zero [pre-dose] extrapolated to infinite time)</measure>
    <time_frame>During treatment and confinement, 7 days after dosing (±1 day), and 30 days after dosing (±3 days).</time_frame>
    <description>Evaluation of the PK after receiving PRS-060</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK assessment: AUC (0-24) (area under the plasma concentration-curve)</measure>
    <time_frame>During treatment and confinement, 7 days after dosing (±1 day), and 30 days after dosing (±3 days).</time_frame>
    <description>Evaluation of the PK after receiving PRS-060</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK assessment: Vz/F (apparent volume of distribution during terminal phase)</measure>
    <time_frame>During treatment and confinement, 7 days after dosing (±1 day), and 30 days after dosing (±3 days).</time_frame>
    <description>Evaluation of the PK after receiving PRS-060</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK assessment: CL/F (apparent oral clearance estimated as dose divided by AUC)</measure>
    <time_frame>During treatment and confinement, 7 days after dosing (±1 day), and 30 days after dosing (±3 days).</time_frame>
    <description>Evaluation of the PK after receiving PRS-060</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK assessment of urine</measure>
    <time_frame>During treatment and confinement</time_frame>
    <description>Evaluation of PRS-060 levels in the urine after receiving PRS-060</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum ADA assessment using bridging Immunoassay Enhanced Chemiluminescence (ECL) method</measure>
    <time_frame>During treatment and confinement, 7 days after dosing (±1 day), and 30 days after dosing (±3 days).</time_frame>
    <description>Evaluation of potential development of ADAs against PRS-060</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FeNO assessment</measure>
    <time_frame>Screening, during treatment and confinement, 7 days after dosing (±1 day), and 30 days after dosing (±3 days).</time_frame>
    <description>Evaluation of FeNO after receiving PRS-060 or placebo</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">76</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>PRS-060</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>PRS-060 or Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>PRS-060 or Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PRS-060</intervention_name>
    <description>Study drug</description>
    <arm_group_label>PRS-060</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Inhalant designed to mimic PRS-060</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Body Mass Index (BMI) of 18 to 35&#xD;
&#xD;
          -  Subjects who are non-smokers or ex-smokers who have smoked no more than twice in 3&#xD;
             months prior to screening (determined by urine continine &lt; 500 ng/mL, at Screening&#xD;
             visit)&#xD;
&#xD;
          -  Males and non-pregnant, non-breastfeeding females&#xD;
&#xD;
          -  Males who are sexually active with women of childbearing potential must agree to&#xD;
             follow a highly effective method(s) of contraception for the duration of treatment&#xD;
             with study drug as well as for an additional 90 days post-treatment completion. Women&#xD;
             of childbearing potential who are sexually active with a fertile male must agree to&#xD;
             follow instructions for double methods of contraception for the duration of their&#xD;
             participation in the trial and for 90 days post-treatment completion&#xD;
&#xD;
          -  Documented diagnosis of mild asthma&#xD;
&#xD;
          -  18 to 55 years of age&#xD;
&#xD;
          -  Lung function ≥ 70% predicted for FEV1 and FEV1/FVC ratio ≥ 0.7&#xD;
&#xD;
          -  FeNO ≥ 35 ppb at Screening and during pre-qualification for the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History or clinical manifestations of any clinically significant medical disorder&#xD;
             that, in the opinion of the investigator, may put the subject at risk because of&#xD;
             participation in the study, influence the results of the study, or affect the&#xD;
             subject's ability to participate in the study&#xD;
&#xD;
          -  A history of drug or alcohol abuse&#xD;
&#xD;
          -  History of, or known significant infection including hepatitis A, B, or C, Human&#xD;
             immunodeficiency Virus (HIV), tuberculosis (i.e., positive result for interferon&#xD;
             [IFN]-γ release assay [IGRA], QuantiFERON® TB-Gold), that may put the subject at risk&#xD;
             during participation in the study&#xD;
&#xD;
          -  History of cancer within the last 10 years (20 years for breast cancer) except for&#xD;
             basal and squamous cell carcinoma of the skin or in situ carcinoma of the cervix&#xD;
             treated and considered cured. Any history of lymphoma is not allowed&#xD;
&#xD;
          -  Any clinically significant illness, infection, medical/surgical procedure, or trauma&#xD;
             within 4 weeks of Day 1 or planned inpatient surgery or hospitalization during the&#xD;
             study period&#xD;
&#xD;
          -  Any clinically significant abnormalities in clinical chemistry, hematology, or&#xD;
             urinalysis results, as judged by the Principal Investigator&#xD;
&#xD;
          -  Significant history of recurrent ongoing 'dry eye syndrome' of any cause that may be&#xD;
             chronic or acute, that may affect the interpretation of safety data associated with&#xD;
             the potential for ADAs targeted to PRS-060 (structurally related to tear lipocalin)&#xD;
&#xD;
          -  Subjects who have received live or attenuated vaccine in the 4 weeks prior to Day 1&#xD;
&#xD;
          -  Subjects with a disease history suggesting abnormal immune function&#xD;
&#xD;
          -  History of anaphylaxis following any biologic therapy and known history of allergy or&#xD;
             reaction to any component of the investigational product formulation&#xD;
&#xD;
          -  Inability to communicate well with the Investigator (i.e., language problem, poor&#xD;
             mental development, or impaired cerebral function)&#xD;
&#xD;
          -  Participation in any clinical study for a New Chemical Entity within the previous 16&#xD;
             weeks or a marketed drug clinical study within the previous 12 weeks or within 5&#xD;
             half-lives, whichever is the longer, before the first dose of study drug&#xD;
&#xD;
          -  Donation of 450 mL or more blood within the previous 12 weeks&#xD;
&#xD;
          -  Women who are pregnant, or breastfeeding, or planning to become pregnant within the&#xD;
             study period or 90 days post-treatment completion&#xD;
&#xD;
          -  Males who are sexually active with a female partner of childbearing potential and who&#xD;
             have not had a vasectomy and who do not agree to a highly effective method of&#xD;
             contraception from Day 1 to 90 days post-treatment completion. Females of childbearing&#xD;
             potential who are sexually active with a fertile male partner who do not agree to&#xD;
             double methods of contraception with at least one barrier from Day 1 to 90 days&#xD;
             post-treatment completion&#xD;
&#xD;
          -  Life-threatening asthmatic episode in the past&#xD;
&#xD;
          -  C-reactive protein (CRP) above 5 mg/L&#xD;
&#xD;
          -  Use of the following medicines within the specified time before screening:&#xD;
&#xD;
               -  Long-acting β2 agonists; none for 4 weeks prior to Screening&#xD;
&#xD;
               -  Anti-IgE or anti-IL-5 therapy; for 6 months prior to Screening&#xD;
&#xD;
               -  Inhaled corticosteroids (&gt; 500 μg per day of beclometasone dipropionate [BDP] or&#xD;
                  equivalent) within 16 weeks prior to Screening&#xD;
&#xD;
               -  Inhaled corticosteroids; none for 4 weeks prior to screening&#xD;
&#xD;
               -  Oral or injectable steroids for the treatment of asthma or respiratory tract&#xD;
                  infection within 5 years prior to Screening&#xD;
&#xD;
               -  Intranasal steroids within 4 weeks prior to Screening&#xD;
&#xD;
               -  Topical steroids within 4 weeks prior to Screening&#xD;
&#xD;
               -  Leukotriene antagonists within 2 weeks prior to Screening&#xD;
&#xD;
               -  Xanthines (excluding caffeine), anticholinergics, or cromoglycate within 1 week&#xD;
                  prior to Screening&#xD;
&#xD;
               -  PRS-060 at anytime&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Q-Pharm</name>
      <address>
        <city>Herston</city>
        <state>Queensland</state>
        <zip>4006</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CMAX</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nucleus Network Limited</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Linear</name>
      <address>
        <city>Nedlands</city>
        <state>West Australia</state>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>June 11, 2018</study_first_submitted>
  <study_first_submitted_qc>June 20, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 2, 2018</study_first_posted>
  <last_update_submitted>December 22, 2020</last_update_submitted>
  <last_update_submitted_qc>December 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Asthma</keyword>
  <keyword>Anticalin</keyword>
  <keyword>PRS-060</keyword>
  <keyword>Pieris</keyword>
  <keyword>IL-4 receptor alpha</keyword>
  <keyword>IL-13</keyword>
  <keyword>IL-4</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

